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Despite recent large-scale profiling efforts, the best prognostic predictor of glioblastoma
multiforme (GBM) remains the patient’s age at diagnosis. We describe a global pattern of
tumor-exclusive co-occurring copy-number alterations (CNAs) that is correlated, possibly
coordinated with GBM patients’ survival and response to chemotherapy. The pattern is
revealed by GSVD comparison of patient-matched but probe-independent GBM and normal
aCGH datasets from The Cancer Genome Atlas (TCGA). We find that, first, the GSVD,
formulated as a framework for comparatively modeling two composite datasets, removes
from the pattern copy-number variations (CNVs) that occur in the normal human genome
(e.g., female-specific X chromosome amplification) and experimental variations (e.g., in
tissue batch, genomic center, hybridization date and scanner), without a-priori knowledge
of these variations. Second, the pattern includes most known GBM-associated changes
in chromosome numbers and focal CNAs, as well as several previously unreported CNAs
in >3% of the patients. These include the biochemically putative drug target, cell cycle-
regulated serine/threonine kinase-encoding TLK2, the cyclin E1-encoding CCNE1, and the
Rb-binding histone demethylase-encoding KDM5A. Third, the pattern provides a better
prognostic predictor than the chromosome numbers or any one focal CNA that it identifies,
suggesting that the GBM survival phenotype is an outcome of its global genotype. The
pattern is independent of age, and combined with age, makes a better predictor than age
alone. GSVD comparison of matched profiles of a larger set of TCGA patients, inclusive of
the initial set, confirms the global pattern. GSVD classification of the GBM profiles of an
independent set of patients validates the prognostic contribution of the pattern.
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The announcement of the first complete sequencing of the human genome in 2000 was a
major milestone that opened a new era in the field of human genomics. It brought promise of
real impact on people’s lives, and it was expected to revolutionize the diagnosis, prevention
and treatment of virtually all human diseases, especially cancer. While there is no denying
that genomic research is having a profound impact on scientific progress, the clinical impact
so far has been modest.
DNA microarrays are commonly used for analyzing the human genome, estimated to be
over 3 billion base pairs long and to contain over 20,000 distinct genes. Microarrays can be
used to detect copy-number variations (CNVs), the phenomenon where certain DNA seg-
ments are either duplicated or deleted. When a CNV is associated with a pathogenic state,
it is considered a copy-number alteration (CNA). Array comparative genomic hybridization
(aCGH) is a microarray-based technique for detecting CNAs at a high resolution. The
technique includes a test DNA sample and a reference DNA control sample, where the test
sample is labeled with a red fluorescent dye, and the control sample is labeled with a green
fluorescent dye. The samples are combined in equal amounts and hybridized to probes on
the microarray. These probes have short DNA sequences representing specific locations
along the genome. Microarray resolution is improving rapidly, and newer platforms have
up to 1 million probes covering short (∼60) base pair segments. The microarray is then
scanned and the ratio of the test and control DNA are measured in all probes. CNAs in the
test sample appear as amplifications (red) or deletions (green) of a certain genomic segment
(Figure 1.1).
1Reprinted with minor revisions and with permission from Public Library of Science (PLoS) One 7
(1), article e30098 (January 2012); C. H. Lee,∗ B. O. Alpert,∗ P. Sankaranarayanan and O. Alter, ”GSVD
Comparison of Patient-Matched Normal and Tumor aCGH Profiles Reveals Global Copy-Number Alterations
Predicting Glioblastoma Multiforme Survival”; http://dx.doi.org/10.1371/journal.pone.0030098.
∗These authors contributed equally to this work.
2Cancer genomics research has shown that a cancer of a certain type is genetically distinct
from patient to patient. For example, clustering analysis of gene expression profiles may
distinguish cancer subtypes based on different gene expression signatures. Identifying and
understanding patterns of genetic alterations that drive tumor development in each case
will allow scientists to better classify tumors. Information about aberrant functional genes
will ultimately allow for clinical implementation of gene-targeted therapies that are tailored
to patients who are most likely to benefit from these therapies. This information will
also improve prognosis prediction which can guide physicians towards the most appropriate
treatment. For instance, it has been shown that ovarian cancer patients with BRCA2
mutations exhibited increased sensitivity to certain chemotherapeutic agents, such as cis-
platin [1].
In 2005, The National Cancer Institute and the National Human Genome Research
Institute launched The Cancer Genome Atlas (TCGA), a billion-dollar, comprehensive
project for cataloguing genetic aberrations associated with cancer, using multiple genome
analysis techniques in large patient cohorts. The project aims to collect large numbers
of high quality tumor and patient-matched normal samples from over 20 cancers. Some of
the techniques used include gene expression profiling, copy-number variation profiling, single
nucleotide polymorphisms genotyping, genome-wide DNA methylation profiling, microRNA
profiling, and exon sequencing. These data are freely provided to the research community.
The first cancer studied by TCGA is glioblastoma multiforme (GBM), the most common
primary brain tumor in adults. GBM arises from the glial cells, which provide support and
protection for the neurons. The cancer is usually detected at a late stage after symptoms
begin to appear, and it is characterized by poor prognosis [2] with patients having a median
survival time of approximately 1 year from the time of diagnosis. GBM tumors exhibit
a range of CNAs, many of which play roles in the cancer’s pathogenesis [3–5]. Recent
large-scale gene expression [6–8] and DNA methylation [9] profiling efforts identified GBM
molecular subtypes, distinguished by small numbers of biomarkers. However, despite these
efforts, GBM’s best prognostic predictor remains the patient’s age at diagnosis [10, 11].
Most GBM studies that have found various prognostic biomarkers did so analyzing gene
expression and methylation data. In this work, we analyze copy-number variation in tumor
and patient-matched normal profiles and identify a pattern that predicts GBM patients’
survival.
The advent of new genomic technologies that produce massive datasets has raised a big
challenge: How can we store such large outputs, let alone analyze them? The growth in raw
3output has outstripped Moore’s Law of advances in information technology and storage
capacity [12]. This is one of the reasons researchers resort to analyzing smaller subsets
of the data, for example choosing genes that are suspected to play roles in the biological
processes under investigation. The singular value decomposition (SVD) is a mathematical
factorization that can reveal significant patterns in large datasets, and has many useful
applications in signal processing and statistics. It is an effective method of reducing the
dimensionality of large-scale datasets which include multiple genomic samples, and it has
been previously used to model DNA microarray data [13].
TCGA provides cancer genomic data using multiple genome analysis techniques in large
patient cohorts. The structure of these data integrated from different studies is of an order
higher than that of a matrix, and there is a fundamental need for mathematical frameworks
suitable for analyzing such large-scale multidimensional data. The development of tools
capable of effectively analyzing these data will help in obtaining biologically meaningful
results, which may translate into clinically relevant information, such as aberrant genes and
patient prognosis.
One such tool for analyzing multidimensional data is the generalized SVD (GSVD),
which can be used to integrate two large-scale matrices of different numbers of rows and
the same numbers of columns. Unlike existing algorithms, the GSVD does not require a
mapping across the different datasets, allowing conservation of a more full range of the data.
It was demonstrated using the GSVD that modeling of DNA microarray data can correctly
predict previously unknown cellular mechanisms [14]. GSVD comparative modeling of
cancer genomic data, therefore, draws a mathematical analogy between the prediction of
cellular modes of regulation and the prognosis of cancers.
1.2 Introduction
To identify CNAs that might predict GBM patients’ survival, we comparatively model
patient-matched GBM and normal aCGH profiles from TCGA by using the GSVD [15].
Previously, we formulated the GSVD as a framework for comparatively modeling two com-
posite datasets [16] (see also [17]), and illustrated its application in sequence-independent
comparison of DNA microarray data from two organisms, where, as we showed, the mathe-
matical variables and operations of the GSVD represent experimental or biological reality.
The variables, subspaces of significant patterns that are uncovered in the simultaneous
decomposition of the two datasets and are mathematically significant in either both (i.e.,
common to both) datasets or only one (i.e., exclusive to one) of the datasets, correlate with
4cellular programs that are either conserved in both or unique to only one of the organisms,
respectively. The operation of reconstruction in the subspaces that are mathematically
common to both datasets outlines the biological similarity in the regulation of the cellular
programs that are conserved across the species. Reconstruction in the common and exclusive
subspaces of either dataset outlines the differential regulation of the conserved relative to
the unique programs in the corresponding organism.
We now find that also in probe-independent comparison of aCGH data from patient-
matched tumor and normal samples, the mathematical variables of the GSVD, i.e., shared
tumor and normal patterns of copy-number variation across the patients and the correspond-
ing tumor- and normal-specific patterns of copy-number variation across the tumor and nor-
mal probes, represent experimental or biological reality. Patterns that are mathematically
significant in both datasets represent CNVs in the normal human genome that are conserved
in the tumor genome (e.g., female-specific X chromosome amplification). Patterns that are
mathematically significant in the normal but not the tumor dataset represent experimental
variations that exclusively affect the normal dataset. Similarly, some patterns that are
mathematically significant in the tumor but not the normal dataset represent experimental
variations that exclusively affect the tumor dataset.
One pattern that is mathematically significant in the tumor but not the normal dataset,
represents tumor-exclusive co-occurring CNAs, including most known GBM-associated changes
in chromosome numbers and focal CNAs, as well as several previously unreported CNAs
in >3% of the patients [18]. This pattern is correlated, possibly coordinated with GBM
patients’ survival and response to therapy. We find that the pattern provides a prognostic
predictor that is better than the chromosome numbers or any one focal CNA that it
identifies, suggesting that the GBM survival phenotype is an outcome of its global genotype.
The pattern is independent of age, and combined with age, makes a better predictor than
age alone.
We confirm our results with GSVD comparison of matched profiles of a larger set of
TCGA patients, inclusive of the initial set. We validate the prognostic contribution of the
pattern with GSVD classification of the GBM profiles of a set of patients that is independent
of both the initial set and the inclusive confirmation set [19].
5Figure 1.1. Array comparative genomic hybridization (aCGH).
CHAPTER 2
METHODS
To compare TCGA patient-matched GBM and normal (mostly blood) aCGH profiles
(Dataset S1 and Mathematica Notebooks S1 and S2), Agilent Human aCGH 244A-measured
365 tumor and 360 normal profiles were selected, corresponding to the sameN=251 patients.
Each profile lists log2 of the TCGA level 1 background-subtracted intensity in the sample
relative to the Promega DNA reference, with signal to background >2.5 for both the sample
and reference in more than 90% of the 223,603 autosomal probes on the microarray. The
profiles are organized in one tumor and one normal dataset, ofM1=212,696 andM2=211,227
autosomal and X chromosome probes, each probe with valid data in at least 99% of either the
tumor or normal arrays, respectively. Each profile is centered at its autosomal median copy
number. The <0.2% missing data entries in the tumor and normal datasets are estimated
by using singular value decomposition (SVD) as described [13, 16, 20–22]. Within each set,
the medians of profiles of samples from the same patient are taken.
The structure of the patient-matched but probe-independent tumor and normal datasets
D1 and D2, of N patients, i.e., N -arrays ×M1-tumor and M2-normal probes, is of an order
higher than that of a single matrix. The patients, the tumor and normal probes as well as
the tissue types, each represent a degree of freedom. Unfolded into a single matrix, some
of the degrees of freedom are lost, limiting the possible interpretations of the data (see
also [23,24].
To compare the tumor and normal datasets, therefore, we use the GSVD, formulated to
simultaneously separate the paired datasets into paired weighted sums of N outer products
of two patterns each: One pattern of copy-number variation across the patients, i.e., a
“probelet” vTn , which is identical for both the tumor and normal datasets, combined with
either the corresponding tumor-specific pattern of copy-number variation across the tumor
probes, i.e., the “tumor arraylet” u1,n, or the corresponding normal-specific pattern across










σ2,nu2,n ⊗ vTn . (2.1)
The probelets are, in general, nonorthonormal, but are normalized, such that vTn vn = 1.
The tumor and normal arraylets are orthonormal, such that UT1 U1 = U
T
2 U2 = I.
The significance of the probelet vTn in either the tumor or normal dataset, in terms of the
overall information that it captures in this dataset, is proportional to either of the weights













The “generalized normalized Shannon entropy” of each dataset,
0 ≤ d1 = (logN)−1
N∑
n=1
p1,n log p1,n ≤ 1,
0 ≤ d2 = (logN)−1
N∑
n=1
p2,n log p2,n ≤ 1, (2.3)
measures the complexity of the data from the distribution of the overall information among
the different probelets and corresponding arraylets. An entropy of zero corresponds to an
ordered and redundant dataset in which all the information is captured by a single probelet
and its corresponding arraylet. An entropy of one corresponds to a disordered and random
dataset in which all probelets and arraylets are of equal significance. The significance of the
probelet vTn in the tumor dataset relative to its significance in the normal dataset is defined
in terms of an “angular distance” θn that is proportional to the ratio of these weights,
− pi/4 ≤ θn = arctan(σ1,n/σ2,n)− pi/4 ≤ pi/4. (2.4)
An angular distance of ±pi/4 indicates a probelet that is exclusive to either the tumor or
normal dataset, respectively, whereas an angular distance of zero indicates a probelet that is
common to both the tumor and normal datasets. The probelets are arranged in decreasing
order of their angular distances, i.e., their significance in the tumor dataset relative to the
normal dataset.
To biologically or experimentally interpret these significant probelets, we correlate or
anticorrelate each probelet with relative copy-number gain or loss across a group of patients
8according to the TCGA annotations of the group of n patients with largest or smallest
relative copy numbers in this probelet among all N patients, respectively. The P -value of
a given association is calculated assuming hypergeometric probability distribution of the
K annotations among the N patients, and of the subset of k ⊆ K annotations among the














We visualize the copy-number distribution between the annotations that are associated
with largest or smallest relative copy numbers in each probelet by using boxplots, and by
calculating the corresponding Mann-Whitney-Wilcoxon P -value (Figures 2.4 and 2.5). To
interpret the corresponding tumor and normal arraylets, we map the tumor and normal
probes onto the National Center for Biotechnology Information (NCBI) human genome
sequence build 36, by using the Agilent Technologies probe annotations posted at the
University of California at Santa Cruz (UCSC) human genome browser [26,27]. We segment
each arraylet and assign each segment a P -value by using the circular binary segmentation
(CBS) algorithm as described (Dataset S2) [28, 29]. We find that the significant probelets
and corresponding tumor and normal arraylets, as well as their interpretations, are robust
to variations in the preprocessing of the data, e.g., in the data selection cutoffs.
9Figure 2.1. Generalized singular value decomposition (GSVD). The data matrices D1 and
D2 are decomposed into matrices with the same dimensions U1 and U2, the square and
diagonal matrices Σ1 and Σ2, and one shared matrix V
T .
10
Figure 2.2. Generalized singular value decomposition (GSVD) of the TCGA patient–
matched tumor and normal aCGH profiles. The structure of the patient-matched but
probe-independent tumor and normal datasets D1 and D2, of the initial set of N=251
patients, i.e., N -arrays × M1=212,696-tumor probes and M2=211,227-normal probes, is of
an order higher than that of a single matrix. The patients, the tumor and normal probes as
well as the tissue types, each represent a degree of freedom. Unfolded into a single matrix,
some of the degrees of freedom are lost and much of the information in the datasets might
also be lost. The GSVD simultaneously separates the paired datasets into paired weighted
sums of N outer products of two patterns each: One pattern of copy-number variation
across the patients, i.e., a “probelet” vTn , which is identical for both the tumor and normal
datasets, combined with either the corresponding tumor-specific pattern of copy-number
variation across the tumor probes, i.e., the “tumor arraylet” u1,n, or the corresponding
normal-specific pattern across the normal probes, i.e., the “normal arraylet” u2,n (Equation
2.1). This is depicted in a raster display, with relative copy-number gain (red), no change
(black) and loss (green), explicitly showing only the first through the 10th and the 242nd
through the 251st probelets and corresponding tumor and normal arraylets, which capture
∼52% and 71% of the information in the tumor and normal dataset, respectively. The
significance of the probelet vTn in the tumor dataset relative to its significance in the normal
dataset is defined in terms of an “angular distance” that is proportional to the ratio of
these weights (Equation 2.4). This is depicted in a bar chart display, showing that the
first and second probelets are almost exclusive to the tumor dataset with angular distances
>2pi/9, the 247th to 251st probelets are approximately exclusive to the normal dataset
with angular distances . −pi/6, and the 246th probelet is relatively common to the normal
and tumor datasets with an angular distance > −pi/6. We find and confirm that the
second most tumor-exclusive probelet, which is also the most significant probelet in the
tumor dataset, significantly correlates with GBM prognosis. The corresponding tumor
arraylet describes a global pattern of tumor-exclusive co-occurring CNAs, including most
known GBM-associated changes in chromosome numbers and focal CNAs, as well as several
previously unreported CNAs, including the biochemically putative drug target-encoding
TLK2 [30–33]. We find and validate that a negligible weight of the global pattern in a
patient’s GBM aCGH profile is indicative of a significantly longer GBM survival time. It
was shown that the GSVD provides a mathematical framework for comparative modeling of
DNA microarray data from two organisms [16, 22]. Recent experimental results [14] verify
a computationally predicted genome-wide mode of regulation [34, 35], and demonstrate
that GSVD modeling of DNA microarray data can be used to correctly predict previously
unknown cellular mechanisms. This GSVD comparative modeling of aCGH data from
patient-matched tumor and normal samples, therefore, draws a mathematical analogy











































































































































































































































































HbL Normal Generalized Fraction
d2 =0.59
Figure 2.3. Most significant probelets in the tumor and normal datasets. (a) Bar chart of
the ten most significant probelets in the tumor dataset in terms of the generalized fraction
that each probelet captures in this dataset (Equation 2.2), showing that the two most
tumor-exclusive probelets, i.e., the first probelet and the second probelet, with angular
distances >2pi/9, are also the two most significant probelets in the tumor dataset, with
∼11% and 22% of the information in this dataset, respectively. The “generalized normalized
Shannon entropy” (Equation 2.3) of the tumor dataset is d1=0.73. (b) Bar chart of the
generalized fractions of the ten most significant probelets in the normal dataset, showing
that the five most normal-exclusive probelets, the 247th to 251st probelets, with angular
distances .−pi/6, are among the seven most significant probelets in the normal dataset,
capturing together ∼56% of the information in this dataset. The 246th probelet (Figure
2.2 d–f ), which is relatively common to the normal and tumor datasets with an angular
distance >−pi/6, is the second most significant probelet in the normal dataset with ∼8% of
the information. The generalized entropy of the normal dataset, d2=0.59, is smaller than
that of the tumor dataset. This means that the normal dataset is more redundant and less






































































































































Figure 2.4. Differences in copy numbers among the TCGA annotations associated with
the significant probelets. Boxplot visualization of the distribution of copy numbers of the
(a) first, most tumor-exclusive probelet among the associated genomic centers where the
GBM samples were hybridized at (Table 2.1); (b) 247th, normal-exclusive probelet among
the dates of hybridization of the normal samples; (c) 248th, normal-exclusive probelet be-
tween the associated tissue batches/hybridization scanners of the normal samples; (d) 249th,
normal-exclusive probelet between the associated tissue batches/hybridization scanners of
the normal samples; (e) 250th, normal-exclusive probelet among the dates of hybridization
of the normal samples; (f ) 251st, most normal-exclusive probelet among the associated ge-
nomic centers where the normal samples were hybridized at. The Mann-Whitney-Wilcoxon
P -values correspond to the two annotations that are associated with largest or smallest






























































HcL Tumor Arraylet 246
P-value`10-38
Figure 2.5. Copy-number distributions of the 246th probelet and the corresponding
246th normal arraylet and 246th tumor arraylet. Boxplot visualization and Mann-Whit-
ney-Wilcoxon P -values of the distribution of copy numbers of the (a) 246th probelet, which
is approximately common to both the normal and tumor datasets, and is the second most
significant in the normal dataset (Figure 2.3b), between the gender annotations (Table 2.1);
(b) 246th normal arraylet between the autosomal and X chromosome normal probes; (c)

















































































































































































































































































































































































































































































































































































































































































































































































We find that, first, the GSVD identifies significant experimental variations that ex-
clusively affect either the tumor or the normal dataset, as well as CNVs that occur in
the normal human genome and are common to both datasets, without a-priori knowledge
of these variations. The mathematically most tumor-exclusive probelet, i.e., the first
probelet (Figure 3.1), correlates with tumor-exclusive experimental variation in the genomic
center where the GBM samples were hybridized at, Harvard Medical School (HMS) or
Memorial Sloan-Kettering Cancer Center (MSKCC), with the P -values < 10−5 (Table 2.1
and Figure 2.4). Similarly, the five most normal-exclusive probelets, i.e., the 247th to
251st probelets (Figures 3.2–3.6), correlate with experimental variations among the normal
samples in genomic center, DNA microarray hybridization or scan date as well as the tissue
batch and hybridization scanner, with P -values < 10−3. Consistently, the corresponding
arraylets, i.e., the first tumor arraylet and the 247th to 251st normal arraylets, describe
copy-number distributions which are approximately centered at zero with relatively large,
chromosome-invariant widths.
We find that the two most tumor-exclusive mathematical patterns of copy-number
variation across the patients, i.e., the first probelet (Figure 3.1) and the second probelet
(Figure 3.7 a–c), with angular distances > 2pi/9, are also the two most significant probelets
in the tumor dataset, with ∼11% and 22% of the information in this dataset, respectively.
Similarly, the five most normal-exclusive probelets, the 247th to 251st probelets (Figures
3.2–3.6), with angular distances . −pi/6, are among the seven most significant probelets in
the normal dataset, capturing together ∼56% of the information in this dataset. The 246th
probelet (Figure 3.7d–f ), which is the second most significant probelet in the normal dataset
with ∼8% of the information, is relatively common to the normal and tumor datasets with
an angular distance > −pi/6.
The 246th probelet (Figure 3.7e), which is mathematically approximately common to
both the normal and tumor datasets, describes copy-number amplification in the female
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relative to the male patients that is biologically common to both the normal and tumor
datasets. Consistently, both the 246th normal arraylet (Figure 3.7d) and 246th tumor
arraylet describe an X chromosome-exclusive amplification. The P -values are < 10−38
(Table 2.1 and Figure 2.5). To assign the patients gender, we calculate for each patient the
standard deviation of the mean X chromosome number from the autosomal genomic mean
in the patient’s normal profile (Figure 3.7f ). Patients with X chromosome amplification
greater than twice the standard deviation are assigned the female gender. For three of the
patients, this copy-number gender assignment conflicts with the TCGA gender annotation.
Upon contacting TCGA, it was confirmed that the TCGA gender assignment in these
three patients was incorrect. For three additional patients, the TCGA gender annotation is
missing. In all six cases, the classification of the patients by the 246th probelet agrees with
the copy-number assignment.
On June 2011, it was noted by the National Human Genome Research Institute that
while genome-wide association studies have identified over 1,200 statistically significant
associations, only 7 such associations have been reported on the X chromosome. This is
mostly due to the exclusion of the X chromosome data from most computational analyses
of large-scale molecular biological data. It is, therefore, of particular significance that our
analysis includes all autosomal and X chromosome probes with valid data in at least 99%
of either the tumor or normal arrays, respectively.
Second, we find that the GSVD identifies a global pattern of tumor-exclusive co-occurring
CNAs that includes most known GBM-associated changes in chromosome numbers and focal
CNAs. This global pattern is described by the second tumor arraylet (Figure 3.7a and
Dataset S3). The second most tumor-exclusive probelet (Figure 3.7b), which describes the
corresponding copy-number variation across the patients, is the most significant probelet
in the tumor dataset. Dominant in the global pattern, and frequently observed in GBM
samples [3], is a co-occurrence of a gain of chromosome 7 and losses of chromosome 10 and
the short arm of chromosome 9 (9p). To assign a chromosome gain or loss, we calculate
for each tumor profile the standard deviation of the mean chromosome number from the
autosomal genomic mean, excluding the outlying chromosomes 7, 9p and 10. The gain of
chromosome 7 and the losses of chromosomes 10 and 9p are greater than twice the standard
deviation in the global pattern as well as the tumor profiles of ∼20%, 41% and 12% of the
patients, respectively.
Focal CNAs that are known to play roles in the origination and development of GBM
and are described by the global pattern include amplifications of segments containing the
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genes MDM4 (1q32.1), AKT3 (1q44), EGFR (7p11.2), MET (7q31.2), CDK4 (12q14.1)
and MDM2 (12q15), and deletions of segments containing the genes CDKN2A/B (9p21.3)
and PTEN (10q23.31), that occur in >3% of the patients. To assign a CNA in a segment,
we calculate for each tumor profile the mean segment copy number. Profiles with segment
amplification or deletion greater than twice the standard deviation from the autosomal
genomic mean, excluding the outlying chromosomes 7, 9p and 10, or greater than one
standard deviation from the chromosomal mean, when this deviation is consistent with the
deviation from the genomic mean, are assigned a segment gain or loss, respectively. The
frequencies of amplification or deletion we observe for these segments are similar to the
reported frequencies of the corresponding focal CNAs [5].
Novel CNAs, previously unrecognized in GBM, are also revealed by the global pattern
[18]. These include an amplification of a segment that contains TLK2 (17q23.2) in ∼22%
of the patients, with the corresponding CBS P -value< 10−140. Copy-number amplification
of TLK2 has been correlated with overexpression in several other cancers [30, 31]. The
human gene TLK2, with homologs in the plant Arabidopsis thaliana but not in the yeast
Saccharomyces cerevisiae, encodes for a multicellular organisms-specific serine/threonine
protein kinase, a biochemically putative drug target [33], which activity is directly dependent
on ongoing DNA replication [32]. On the same segment with TLK2, we also find the gene
METTL2A. Another amplified segment (CBS P -value< 10−13) contains the homologous
gene METTL2B (7q32.1). Overexpression of METTL2A/B was linked with prostate cancer
metastasis [36], cAMP response element-binding (CREB) regulation in myeloid leukemia
[37], and breast cancer patients’ response to chemotherapy [38].
An amplification of a segment (CBS P -value< 10−145) encompassing the cyclin E1-
encoding CCNE1 (19q12) is revealed in ∼4% of the patients. Cyclin E1 regulates entry into
the DNA synthesis phase of the cell division cycle. Copy number increases of CCNE1 have
been linked with multiple cancers [39–41], but not GBM. Amplicon-dependent expression
of CCNE1, together with the genes POP4, PLEKHF1, C19orf12 and C19orf2 that flank
CCNE1 on this segment, was linked with primary treatment failure in ovarian cancer,
possibly due to rapid repopulation of the tumor after chemotherapy [42].
Another rare amplification in ∼4% of the patients, of a segment (CBS P -value< 10−28)
that overlaps with the 5’ end of KDM5A (12p13.33), is also revealed. The protein en-
coded by KDM5A, a retinoblastoma tumor suppressor (Rb)-binding lysine-specific histone
demethylase [43], has been recently implicated in cancer drug tolerance [44]. The same
amplified segment includes the solute carrier (SLC) sodium-neurotransmitter symporters
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SLC6A12/13, biochemically putative carriers of drugs that might overcome the blood-brain
barrier [45]. On the same segment we also find IQSEC3, a mature neuron-specific gua-
nine nucleotide exchange factor for the ADP-ribosylation factor ARF1, a key regulator of
intracellular membrane traffic [46].
Note that although the tumor samples exhibit female-specific X chromosome amplifi-
cation (Figure 3.7c), the second tumor arraylet exhibits an unsegmented X chromosome
copy-number distribution, that is approximately centered at zero with a relatively small
width. This illustrates the mathematical separation of the global pattern of tumor-exclusive
co-occurring CNAs, that is described by the second tumor arraylet, from all other biological
and experimental variations that compose either the tumor or the normal dataset, such as
the gender variation that is common to both datasets, and is described by the 246th probelet
and the corresponding 246th tumor and 246th normal arraylets.
Third, we find that the GSVD classifies the patients into two groups of significantly
different prognoses. The classification is according to the copy numbers listed in the second
probelet, which correspond to the weights of the second tumor arraylet in the GBM aCGH
profiles of the patients. A group of 227 patients, 224 of which with TCGA annotations,
displays high (>0.02) relative copy numbers in the second probelet, and a Kaplan-Meier
(KM) [47] median survival time of ∼13 months (Figure 3.8a). A group of 23 patients,
i.e., ∼10% of the patients, displays low, approximately zero, relative copy numbers in the
second probelet, and a KM median survival time of ∼29 months, which is more than twice
as long as that of the previous group. The corresponding log-rank test P -value is < 10−3.
The univariate Cox [48] proportional hazard ratio is 2.3, with a P -value < 10−2 (Table
3.1), meaning that high relative copy numbers in the second probelet confer more than
twice the hazard of low numbers. Note that the cutoff of ±0.02 was selected to enable
classification of as many of the patients as possible. Only one of the 251 patients has a
negative copy number in the second probelet <-0.02, and remains unclassified. This patient
is also missing the TCGA annotations. Survival analysis of only the chemotherapy patients
classified by GSVD gives similar results (Table 3.2 and Figure 3.9a). The P -values are
calculated without adjusting for multiple comparisons [49]. We observe, therefore, that a
negligible weight of the global pattern in a patient’s GBM aCGH profile is indicative of
a significantly longer survival time, as well as an improved response to treatment among
chemotherapy patients.
A mutation in the gene IDH1 was recently linked with improved GBM prognosis [2, 7]
and associated with a CpG island methylator phenotype [9]. We find, however, only seven
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patients (six chmeotherapy patients), i.e., <3%, with IDH1 mutation. This is less than a
third of the 23 patients in the long-term survival group defined by the global pattern. The
corresponding survival analyses are, therefore, statistically insignificant (Figures 3.10 and
3.11).
Chromosome 10 loss, chromosome 7 gain and even loss of 9p, which are dominant in
the global pattern, have been suggested as indicators of poorer GBM prognoses for over
two decades [3, 4]. However, the KM survival curves for the groups of patients with either
one of these chromosome number changes almost overlap the curves for the patients with
no changes (Figure 3.12). The log-rank test P -values for all three classifications are &
10−1, with the median survival time differences .3 months. Similarly, in the KM survival
analyses of the groups of patients with either a CNA or no CNA in either one of the 130
segments identified by the global pattern (Figure 3.13), log-rank test P -values < 5 × 10−2
are calculated for only 12 of the classifications. Of these, only six correspond to a KM
median survival time difference that is &5 months, approximately a third of the ∼16 months
difference observed for the GSVD classification.
One of these segments contains the genes TLK2 and METTL2A and another segment
contains the homologous gene METTL2B, previously unrecognized in GBM. The KM
median survival times we calculate for the 56 patients with TLK2/METTL2A amplification
and, separately, for the 19 patients with METTL2B amplifications are ∼5 and 8 months
longer than that for the remaining patients in each case. Similarly, the KM median survival
times we calculate for the 43 chemotherapy patients with TLK2/METTL2A amplification
and, separately, for the 15 chemotherapy patients with METTL2B amplification, are both
∼7 months longer than that for the remaining chemotherapy patients in each case (Fig-
ure 3.14). This suggests that drug-targeting the kinase that TLK2 encodes and/or the
methyltransferase-like proteins that METTL2A/B encode may affect not only the patho-
genesis but also the prognosis of GBM as well as the patient’s response to chemotherapy.
Taken together, we find that the global pattern provides a better prognostic predictor
than the chromosome numbers or any one focal CNA that it identifies. This suggests that
the GBM survival phenotype is an outcome of its global genotype.
Despite the recent genome-scale molecular profiling efforts, age at diagnosis remains the
best prognostic predictor for GBM in clinical use. The KM median survival time difference
between the patients >50 or <50 years old at diagnosis is ∼11 months, approximately two
thirds of the ∼16 months difference observed for the global pattern, with the log-rank test
P -value < 10−4 (Figure 3.8b). The univariate Cox proportional hazard ratio we calculate
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for age is 2, i.e., similar to that for the global pattern. Taken together, the prognostic
contribution of the global pattern is comparable to that of age. Similarly we find that the
prognostic contribution of the global pattern is comparable to that of chemotherapy (Figure
3.15a).
To examine whether the weight of the global pattern in a patient’s GBM aCGH profile is
correlated with the patient’s age at diagnosis, we classify the patients into four groups, with
prognosis of longer-term survival according to both, only one or neither of the classifications
(Figure 3.8c). The KM curves for these four groups are significantly different, with the
log-rank test P -value < 10−4. Within each age group, the subgroup of patients with low
relative copy numbers in the second probelet consistently exhibits longer survival than the
remaining patients. The median survival time of the 16 patients <50 years old at diagnosis
with low copy numbers in the second probelet is ∼34 months, almost three times longer
than the ∼12 months median survival time of the patients >50 years old at diagnosis with
high numbers in the second probelet. The multivariate Cox proportional hazard ratios for
the global pattern and age are 1.8 and 1.7, respectively, with both corresponding P -values
< 3 × 10−2. This survival model relates the time that passed before a patient dies to the
global pattern and age covariates, accounting for censoring (time of last patient follow-up).
These ratios are similar, meaning that both a high weight of the global pattern in a patient’s
GBM aCGH profile and an age >50 years old at diagnosis confer similar relative hazard.
These ratios also do not differ significantly from the univariate ratios of 2.3 and 2 for
the global pattern and age, respectively. Taken together, the prognostic contribution of
the global pattern is not only comparable to that of age, but is also independent of age.
Combined with age, the global pattern makes a better predictor than age alone, with a
combined hazard ratio of ∼3 (multiplying hazard ratios 1.8 and 1.7). We note that the
sample size for the group of patients >50 years old with a low weight of the global pattern
is small and consists of only 7 patients, therefore the added prognostic contribution of the
global pattern is more significant for the group of patients who are <50 years old. Similarly,
we find that the global pattern is independent of chemotherapy (Figure 3.15b).
To confirm the global pattern, we use GSVD to compare matched profiles of a larger,
more recent, set of 344 TCGA patients, that is inclusive of the initial set of 251 patients [19].
Agilent Human aCGH 244A-measured 458 tumor and 459 normal profiles were selected,
corresponding to the inclusive confirmation set of N=344 patients (Dataset S4). The
profiles, centered at their autosomal median copy numbers, are organized in one tumor and
one normal dataset, of M1=200,139 and M2=198,342 probes, respectively. Within each set,
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the medians of profiles of samples from the same patient are taken after estimating missing
data by using SVD. We find that the significant probelets and corresponding tumor and
normal arraylets, as well as their interpretations, are robust to the increase from 251 patients
in the initial set to 344 patients in the inclusive confirmation set, and the accompanying
decreases in tumor and normal probes, respectively.
The second tumor arraylet computed by GSVD for the 344 patients of the inclusive
confirmation set correlates with that of the initial set, with the correlation ∼0.99. To classify
the patients according to the copy numbers listed in the corresponding second probelet of
the inclusive confirmation set, the classification cutoff ±0.02 of the initial set of 251 patients
is scaled by the norm of the copy numbers listed for these patients, resulting in the cutoff
±0.017. Only four of the 251 patients in the initial set, i.e., ∼1.5%, with copy numbers that
are near the classification cutoffs of both sets, change classification. Of the 344 patients, we
find that 315 patients, 309 with TCGA annotations, display high (>0.017) and 27, i.e., ∼8%,
display low, approximately zero, relative copy numbers in the second probelet. Only two
patients, one missing TCGA annotations, remain unclassified with large negative (<-0.017)
copy numbers in the second probelet. Survival analyses of the inclusive confirmation set of
344 patients give qualitatively the same results as these of the initial set of 251 patients.
These analyses confirm that a negligible weight of the global pattern, which is described by
the second tumor arraylet, i.e., a low copy number in the second probelet, is indicative of a
significantly longer survival time (Figure 3.8d). Survival analysis of only the chemotherapy
patients in the inclusive confirmation set classified by GSVD gives similar results (Figure
3.9b). These analyses confirm that the prognostic contribution of the global pattern is
comparable to that of age (Figure 3.8e) and is independent of age (Figure 3.8f ). Similarly,
we confirm that the global pattern is independent of chemotherapy (Figures 3.15 c and d).
To validate the prognostic contribution of the global pattern, we classify GBM profiles
of an independent set of 184 TCGA patients, that is mutually exclusive of the initial set
of 251 patients. Agilent Human aCGH 244A-measured 280 tumor profiles were selected,
corresponding to the independent validation set of 184 patients with available TCGA status
annotations (Dataset S5). Each profile lists relative copy numbers in more than 97.5% of
the 206,820 autosomal probes among the M1=212,696 probes that define the second tumor
arraylet computed by GSVD for the 251 patients of the initial set. Medians of profiles of
samples from the same patient are taken. To classify the 184 patients according to the
correlations of their GBM profiles with the second tumor arraylet of the initial set, the
classification cutoff of the initial set of 251 patients is scaled by the norm of the correlations
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calculated for these patients, resulting in the cutoff ±0.15. For the profiles of 162 patients
we calculate high (>0.15) and for 21, i.e., ∼11%, low, approximately zero, correlation with
the second tumor arraylet. One patient remains unclassified with a large negative (<-0.15)
correlation.
We find that survival analyses of the independent validation set of 184 patients give
qualitatively the same results as these of the initial set of 251 patients and the inclusive
confirmation set of 344 patients (Figures 3.8 g–i and Figures 3.9c, and 3.15 e and f ). These
analyses validate the prognostic contribution of the global pattern, which is computed by
GSVD of patient-matched tumor and normal aCGH profiles, also for patients with measured
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Figure 3.1. The first most tumor-exclusive probelet and corresponding tumor arraylet
uncovered by GSVD of the patient-matched GBM and normal aCGH profiles. (a) Plot
of the first tumor arraylet describes unsegmented chromosomes (black lines), each with
copy-number distributions which are approximately centered at zero with relatively large,
chromosome-invariant widths. The probes are ordered, and their copy numbers are colored,
according to each probe’s chromosomal location. (b) Plot of the first most tumor-exclusive
probelet, which is also the second most significant probelet in the tumor dataset (Figure
2.3a), describes the corresponding variation across the patients. The patients are ordered
according to each patient’s relative copy number in this probelet. These copy numbers
significantly correlate with the genomic center where the GBM samples were hybridized at,
HMS (red), MSKCC (blue) or multiple locations (gray), with the P -values <10−5 (Table
2.1 and Figure 2.4a). (c) Raster display of the tumor dataset, with relative gain (red), no
change (black) and loss (green) of DNA copy numbers, shows the correspondence between
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Figure 3.2. The 247th, normal-exclusive probelet and corresponding normal arraylet
uncovered by GSVD. (a) Plot of the 247th normal arraylet describes copy-number distribu-
tions which are approximately centered at zero with relatively large, chromosome-invariant
widths. The normal probes are ordered, and their copy numbers are colored, according
to each probe’s chromosomal location. (b) Plot of the 247th probelet describes the
corresponding variation across the patients. Copy numbers in this probelet correlate
with the date of hybridization of the normal samples, 7.22.2009 (red), 10.8.2009 (blue)
or other (gray), with the P -values <10−3 (Table 2.1 and Figure 2.4b). (c) Raster display
of the normal dataset shows the correspondence between the normal profiles and the 247th
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Figure 3.3. The 248th, normal-exclusive probelet and corresponding normal arraylet
uncovered by GSVD. (a) Plot of the 248th normal arraylet describes copy-number dis-
tributions which are approximately centered at zero with relatively large, chromosome-in-
variant widths. (b) Plot of the 248th probelet describes the corresponding variation
across the patients. Copy numbers in this probelet significantly correlate with the tissue
batch/hybridization scanner of the normal samples, HMS 8/2331 (red) and other (gray),
with the P -values <10−12 (Table 2.1 and Figure 2.4c). (c) Raster display of the normal
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Figure 3.4. The 249th, normal-exclusive probelet and corresponding normal arraylet
uncovered by GSVD. (a) Plot of the 249th normal arraylet describes copy-number dis-
tributions which are approximately centered at zero with relatively large, chromosome-in-
variant widths. (b) Plot of the 249th probelet describes the corresponding variation
across the patients. Copy numbers in this probelet significantly correlate with the tissue
batch/hybridization scanner of the normal samples, HMS 8/2331 (red) and other (gray),
with the P -values <10−12 (Table 2.1 and Figure 2.4d). (c) Raster display of the normal
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Figure 3.5. The 250th, normal-exclusive probelet and corresponding normal arraylet
uncovered by GSVD. (a) Plot of the 250th normal arraylet describes copy-number distribu-
tions which are approximately centered at zero with relatively large, chromosome-invariant
widths. (b) Plot of the 250th probelet describes the corresponding variation across the
patients. Copy numbers in this probelet correlate with the date of hybridization of
the normal samples, 4.18.2007 (red), 7.22.2009 (blue) or other (gray), with the P -values
<10−3 (Table 2.1 and Figure 2.4e). (c) Raster display of the normal dataset shows the
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Figure 3.6. The first most normal-exclusive, i.e., 251st probelet and corresponding normal
arraylet uncovered by GSVD. (a) Plot of the 251st normal arraylet describes unsegmented
chromosomes (black lines), each with copy-number distributions which are approximately
centered at zero with relatively large, chromosome-invariant widths. (b) Plot of the first
most normal-exclusive probelet, which is also the most significant probelet in the normal
dataset (Figure 2.3b), describes the corresponding variation across the patients. Copy
numbers in this probelet significantly correlate with the genomic center where the normal
samples were hybridized at, HMS (red), MSKCC (blue) or multiple locations (gray), with
the P -values <10−13 (Table 2.1 and Figure 2.4f ). (c) Raster display of the normal dataset
shows the correspondence between the normal profiles and the 251st probelet and normal
arraylet.
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Figure 3.7. Significant probelets and corresponding tumor and normal arraylets uncovered
by GSVD of the patient-matched GBM and normal aCGH profiles. (a) Plot of the second
tumor arraylet describes a global pattern of tumor-exclusive co-occurring CNAs across the
tumor probes. The probes are ordered, and their copy numbers are colored, according to
each probe’s chromosomal location. Segments (black lines) identified by circular binary
segmentation (CBS) [28,29] include most known GBM-associated focal CNAs (black), e.g.,
EGFR amplification. CNAs previously unrecognized in GBM (red) include an amplification
of a segment containing the biochemically putative drug target-encoding TLK2. (b) Plot of
the second most tumor-exclusive probelet, which is also the most significant probelet in the
tumor dataset (Figure 2.3a), describes the corresponding variation across the patients. The
patients are ordered and classified according to each patient’s relative copy number in this
probelet. There are 227 patients (blue) with high (>0.02) and 23 patients (red) with low,
approximately zero, numbers in the second probelet. One patient (gray) remains unclassified
with a large negative (<-0.02) number. This classification significantly correlates with GBM
survival times (Figure 3.8a and Table 3.1). (c) Raster display of the tumor dataset, with
relative gain (red), no change (black) and loss (green) of DNA copy numbers, shows the
correspondence between the GBM profiles and the second probelet and tumor arraylet.
Chromosome 7 gain and losses of chromosomes 9p and 10, which are dominant in the
second tumor arraylet (Figure 3.7a), are negligible in the patients with low copy numbers
in the second probelet, but distinct in the remaining patients (Figure 3.7b). This illustrates
that the copy numbers listed in the second probelet correspond to the weights of the second
tumor arraylet in the GBM profiles of the patients. (d) Plot of the 246th normal arraylet
describes an X chromosome-exclusive amplification across the normal probes. (e) Plot
of the 246th probelet, which is approximately common to both the normal and tumor
datasets, and is the second most significant in the normal dataset (Figure 2.3b), describes
the corresponding copy-number amplification in the female (red) relative to the male (blue)
patients. Classification of the patients by the 246th probelet agrees with the copy-number
gender assignments (Table 3.1 and Figure 2.5), also for three patients with missing TCGA
gender annotations and three additional patients with conflicting TCGA annotations and
copy-number gender assignments. (f ) Raster display of the normal dataset shows the
correspondence between the normal profiles and the 246th probelet and normal arraylet. X
chromosome amplification, which is dominant in the 246th normal arraylet (Figure 3.7d),
is distinct in the female but nonexisting in the male patients (Figure 3.7e). Note also that
although the tumor samples exhibit female-specific X chromosome amplification (Figure
3.7c), the second tumor arraylet (Figure 3.7a) exhibits an unsegmented X chromosome
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Figure 3.8. Survival analyses of the three sets of patients classified by GSVD, age at
diagnosis or both. (a) Kaplan-Meier (KM) [47] curves for the 247 patients with TCGA
annotations in the initial set of 251 patients, classified by copy numbers in the second
probelet, which is computed by GSVD for the 251 patients, show a median survival time
difference of ∼16 months, with the corresponding log-rank test P -value < 10−3. The
univariate Cox [48] proportional hazard ratio is 2.3, with a P -value < 10−2 (Table 3.1),
meaning that high relative copy numbers in the second probelet confer more than twice
the hazard of low numbers. The P -values are calculated without adjusting for multiple
comparisons [49]. (b) Survival analyses of the 247 patients classified by age, i.e., >50 or
<50 years old at diagnosis, show that the prognostic contribution of age, with a KM median
survival time difference of ∼11 months and a univariate Cox hazard ratio of 2, is comparable
to that of GSVD. (c) Survival analyses of the 247 patients classified by both GSVD and age,
show similar multivariate Cox hazard ratios, of 1.8 and 1.7, that do not differ significantly
from the corresponding univariate hazard ratios, of 2.3 and 2, respectively. This means
that GSVD and age are independent prognostic predictors. With a KM median survival
time difference of ∼22 months, GSVD and age combined make a better predictor than age
alone. (d) Survival analyses of the 334 patients with TCGA annotations and a GSVD
classification in the inclusive confirmation set of 344 patients, classified by copy numbers in
the second probelet, which is computed by GSVD for the 344 patients, show a KM median
survival time difference of ∼16 months and a univariate hazard ratio of 2.4, and confirm the
survival analyses of the initial set of 251 patients. (e) Survival analyses of the 334 patients
classified by age confirm that the prognostic contribution of age, with a KM median survival
time difference of ∼10 months and a univariate hazard ratio of 2, is comparable to that of
GSVD. (f ) Survival analyses of the 334 patients classified by both GSVD and age, show
similar multivariate Cox hazard ratios, of 1.9 and 1.8, that do not differ significantly from
the corresponding univariate hazard ratios, and a KM median survival time difference of
∼22 months, with the corresponding log-rank test P -value < 10−5. This confirms that
the prognostic contribution of GSVD is independent of age, and that combined with age,
GSVD makes a better predictor than age alone. (g) Survival analyses of the 183 patients
with a GSVD classification in the independent validation set of 184 patients, classified
by correlations of each patient’s GBM profile with the second tumor arraylet, which is
computed by GSVD for the 251 patients, show a KM median survival time difference of
∼12 months and a univariate hazard ratio of 2.9, and validate the survival analyses of
the initial set of 251 patients. (h) Survival analyses of the 183 patients classified by age
validate that the prognostic contribution of age is comparable to that of GSVD. (i) Survival
analyses of the 183 patients classified by both GSVD and age, show similar multivariate
Cox hazard ratios, of 2 and 2.2, and a KM median survival time difference of ∼41 months,
with the corresponding log-rank test P -value < 10−5. This validates that the prognostic
contribution of GSVD is independent of age, and that combined with age, GSVD makes a
better predictor than age alone, also for patients with measured GBM aCGH profiles in the










































































































































































































































































































































HcL Arraylet 2 HCorr.L
P-value=5.3 ´ 10-3
Figure 3.9. Kaplan-Meier (KM) survival analyses of only the chemotherapy patients from






































Figure 3.10. KM survival analysis of the initial set of 251 patients classified by a mutation










































Figure 3.11. KM survival analysis of only the chemotherapy patients in the initial set,


























































Figure 3.12. KM survival analyses of the initial set of 251 patients classified by GB-
M-associated chromosome number changes. (a) Analysis of the 247 patients with TCGA
annotations in the initial set of 251 patients, classified by number changes in chromosome 10,
shows almost overlapping Kaplan-Meier (KM) [36] curves with a KM median survival time
difference of ∼2 months, and a corresponding log-rank test P -value ∼10−1, meaning that
chromosome 10 loss, frequently observed in GBM, is a poor predictor of GBM patients’
survival. (b) KM survival analysis of the 247 patients classified by number changes in
chromosome 7 shows almost overlapping KM curves with a KM median survival time
difference of <one month, and a corresponding log-rank test P -value >5×10−1, meaning
that chromosome 7 gain is a poor predictor of GBM survival. (c) KM survival analysis
of the 247 patients classified by number changes in chromosome 9p shows a KM median
survival time difference of ∼3 months, and a log-rank test P -value >10−1, meaning that
chromosome 9p loss is a poor predictor of GBM survival.
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Figure 3.13. KM survival analyses of the initial set of 251 patients classified by copy
number changes in selected segments containing GBM-associated genes or genes previously
unrecognized in GBM. In the KM survival analyses of the groups of patients with either
a CNA or no CNA in either one of the 130 segments identified by the global pattern,
i.e., the second tumor-exclusive arraylet (Dataset S3), log-rank test P -values <5×10−2
are calculated for only 12 of the classifications. Of these, only six correspond to a KM
median survival time difference that is &5 months, approximately a third of the ∼16
months difference observed for the GSVD classification. One of these segments contains the
genes TLK2 and METTL2A, previously unrecognized in GBM. The KM median survival
time we calculate for the 56 patients with TLK2 amplification is ∼5 months longer than
that for the remaining patients. This suggests that drug-targeting the kinase and/or the
methyltransferase-like protein that TLK2 and METTL2A encode, respectively, may affect
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Figure 3.14. KM survival analyses of only the chemotherapy patients in the initial set
classified by copy number changes in selected segments.
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Figure 3.15. Survival analyses of the patients from the three sets classified by chemother-
apy alone or GSVD and chemotherapy both. (a) KM and Cox survival analyses of the 236
patients with TCGA chemotherapy annotations in the initial set of 251 patients, classified by
chemotherapy, show that lack of chemotherapy, with a KM median survival time difference
of ∼10 months and a univariate hazard ratio of 2.6 (Table 3.2), confers more than twice the
hazard of chemotherapy. (b) Survival analyses of the 236 patients classified by both GSVD
and chemotherapy, show similar multivariate Cox hazard ratios, of 3 and 3.1, respectively.
This means that GSVD and chemotherapy are independent prognostic predictors. With a
KM median survival time difference of ∼30 months, GSVD and chemotherapy combined
make a better predictor than chemotherapy alone. (c) Survival analyses of the 317 patients
with TCGA chemotherapy annotations in the inclusive confirmation set of 344 patients,
classified by chemotherapy, show a KM median survival time difference of ∼11 months
and a univariate hazard ratio of 2.7, and confirm the survival analyses of the initial
set of 251 patients. (d) Survival analyses of the 317 patients classified by both GSVD
and chemotherapy show similar multivariate Cox hazard ratios, of 3.1 and 3.2, and a
KM median survival time difference of ∼30 months, with the corresponding log-rank test
P -value <10−17. This confirms that the prognostic contribution of GSVD is independent of
chemotherapy, and that combined with chemotherapy, GSVD makes a better predictor than
chemotherapy alone. (e) Survival analyses of the 154 patients with TCGA chemotherapy
annotations in the independent validation set of 184 patients, classified by chemotherapy,
show a KM median survival time difference of ∼11 months and a univariate hazard ratio of
2.2, and validate the survival analyses of the initial set of 251 patients. (f ) Survival analyses
of the 154 patients classified by both GSVD and chemotherapy, show similar multivariate
Cox hazard ratios, of 3.3 and 2.7, and a KM median survival time difference of ∼43 months.
This validates that the prognostic contribution of GSVD is independent of chemotherapy,
and that combined with chemotherapy, GSVD makes a better predictor than chemotherapy
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Previously, we showed that the GSVD provides a mathematical framework for sequence-
independent comparative modeling of DNA microarray data from two organisms, where the
mathematical variables and operations represent experimental or biological reality [16, 22].
The variables, subspaces of significant patterns that are common to both or exclusive to
either one of the datasets, correlate with cellular programs that are conserved in both or
unique to either one of the organisms, respectively. The operation of reconstruction in the
subspaces common to both datasets outlines the biological similarity in the regulation of
the cellular programs that are conserved across the species. Reconstruction in the common
and exclusive subspaces of either dataset outlines the differential regulation of the conserved
relative to the unique programs in the corresponding organism. Recent experimental results
[14] verify a computationally predicted genome-wide mode of regulation [34, 35, 50], and
demonstrate that GSVD modeling of DNA microarray data can be used to correctly predict
previously unknown cellular mechanisms.
Recently, we mathematically defined a higher-order GSVD (HO GSVD) for more than
two large-scale matrices with different row dimensions and the same column dimension
[17]. We proved that this novel HO GSVD extends to higher orders almost all of the
mathematical properties of the GSVD. We showed, comparing global mRNA expression
from the three disparate organisms S. pombe, S. cerevisiae and human, that the HO
GSVD provides a sequence-independent comparative framework for more than two genomic
datasets, where the variables and operations represent experimental or biological reality.
The approximately common HO GSVD subspace represents biological similarity among the
organisms. Simultaneous reconstruction in the common subspace removes the experimental
artifacts, which are dissimilar, from the datasets.
We now show that also in probe-independent comparison of aCGH data from patient-
matched tumor and normal samples, the mathematical variables of the GSVD, i.e., shared
probelets and the corresponding tumor- and normal-specific arraylets, represent experi-
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mental or biological reality. Probelets that are mathematically significant in both datasets,
correspond to normal arraylets representing copy-number variations (CNVs) in the normal
human genome that are conserved in the tumor genome (e.g., female-specific X chromosome
amplification) and are represented by the corresponding tumor arraylets. Probelets that are
mathematically significant in the normal but not the tumor dataset represent experimental
variations that exclusively affect the normal dataset. Similarly, some probelets that are
mathematically significant in the tumor but not the normal dataset represent experimental
variations that exclusively affect the tumor dataset.
We find that the mathematically second most tumor-exclusive probelet, which is also the
mathematically most significant probelet in the tumor dataset, is statistically correlated,
possibly biologically coordinated with GBM patients’ survival and response to chemother-
apy. The corresponding tumor arraylet describes a global pattern of tumor-exclusive co-
occurring CNAs, including most known GBM-associated changes in chromosome numbers
and focal CNAs, as well as several previously unreported CNAs, including the biochemically
putative drug target-encoding TLK2 [18]. We find that a negligible weight of the second
tumor arraylet in a patient’s GBM aCGH profile, mathematically defined by either the
corresponding copy number in the second probelet, or by the correlation of the GBM
profile with the second arraylet, is indicative of a significantly longer GBM survival time.
This GSVD comparative modeling of aCGH data from patient-matched tumor and normal
samples, therefore, draws a mathematical analogy between the prediction of cellular modes
of regulation and the prognosis of cancers.
We confirm our results with GSVD comparison of matched profiles of a larger set of
TCGA patients, inclusive of the initial set. We validate the prognostic contribution of the
pattern with GSVD classification of the GBM profiles of a set of patients that is independent
of both the initial set and the inclusive confirmation set [19].
Additional possible applications of the GSVD (and also the HO GSVD) in personalized
medicine include comparisons of multiple patient-matched datasets, each corresponding to
either (i) a set of large-scale molecular biological profiles (such as DNA copy numbers)
acquired by a high-throughput technology (such as DNA microarrays) from the same tissue
type (such as tumor or normal); or (ii) a set of biomedical images or signals; or (iii) a
set of anatomical or clinical pathology test results or phenotypical observations (such as
age). GSVD comparisons can uncover the relations and possibly even causal coordinations
between these different recorded aspects of the same medical phenomenon.
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GSVD comparisons can be used to determine a single patient’s medical status in relation to




Mathematica Notebook S1. Generalized singular value decomposition (GSVD)
of the TCGA patient-matched tumor and normal aCGH profiles. A Mathematica




Mathematica Notebook S2. Generalized singular value decomposition (GSVD)
of the TCGA patient-matched tumor and normal aCGH profiles. A PDF format
file, readable by Adobe Acrobat Reader.
(PDF)
Dataset S1. Initial set of 251 patients. A tab-delimited text format file, readable by
both Mathematica and Microsoft Excel, reproducing The Cancer Genome Atlas (TCGA) [5]
annotations of the initial set of 251 patients and the corresponding normal and tumor sam-
ples. The tumor and normal profiles of the initial set of 251 patients, in tab-delimited text
format files, tabulating log2 relative copy number variation across 212,696 and 211,227 tu-
mor and normal probes, respectively, are available at http://www.alterlab.org/GBM prognosis/.
(TXT)
Dataset S2. Segments of the significant tumor and normal arraylets, computed
by GSVD for the initial set of 251 patients. A tab-delimited text format file, readable
by both Mathematica and Microsoft Excel, tabulating segments identified by circular binary
segmentation (CBS) [28,29].
(TXT)
Dataset S3. Segments of the second tumor arraylet, computed by GSVD for
the initial set of 251 patients. A tab-delimited text format file, readable by both
Mathematica and Microsoft Excel, tabulating, for each of the 130 CBS segments of the
second tumor arraylet, the segment’s coordinates, the CBS P -value, and the log-rank test
P -value corresponding to the Kaplan-Meier (KM) survival analysis of the initial set of 251
patients classified by either a gain or a loss of this segment.
(TXT)
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Dataset S4. Inclusive confirmation set of 344 patients. A tab-delimited text
format file, readable by both Mathematica and Microsoft Excel, reproducing the TCGA
annotations of the inclusive confirmation set of 344 patients. The tumor and normal profiles
of the inclusive confirmation set of 344 patients, in tab-delimited text format files, tabulating
log2 relative copy number variation across 200,139 and 198,342 tumor and normal probes,
respectively, are available at http://www.alterlab.org/GBM prognosis/.
(TXT)
Dataset S5. Independent validation set of 184 patients. A tab-delimited text format
file, readable by both Mathematica and Microsoft Excel, reproducing the TCGA annota-
tions of the independent validation set of 184 patients. Tumor profiles of the independent
validation set of 184 patients, in a tab-delimited text format file, tabulating log2 relative
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